Standpoint Research’s top analyst Ronnie Moas was out pounding the table on Opko Health Inc. (NASDAQ:OPK) Friday, reiterating a Buy rating and price target of $14.
Opko Health Inc. (NASDAQ:OPK) reports financial and operating results for the three months ended December 31, 2016.
Opko Health Inc. (NASDAQ:OPK) announced the promotion of Thomas Nusbickel to the newly created position of Chief Commercial Officer of OPKO Health’s Renal …
Opko Health Inc. (NASDAQ:OPK) announced that its subsidiary and business unit, GeneDx, is entering into a collaboration with the Deciphering Developmental Disorder (DDD) …
Opko Health Inc. (NASDAQ:OPK) announced the initiation of a multi-center clinical validation study for the Company’s proprietary Total PSA microfluidic assay cassette running …
Opko Health Inc. (NASDAQ:OPK) announced that it will commence shipments of RAYALDEE™ (calcifediol) extended-release capsules to distributors in the United States on Tuesday, …
By Brett Eversole U.S.
Opko Health Inc. (NASDAQ:OPK) reports financial and operating results for the three months endedSeptember 30, 2016.
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
Opko Health Inc. (NASDAQ:OPK) shares tumbled 5% after the Palmetto GBA Medicare Administrative Contractor (MAC) issued a final non-coverage decision for 4Kscore, calling …
